ATE218363T1 - Verwendung von vip analoge für vorbeugung und behandlung von gehirnbeschädigungen von menschlichen neugeborenen - Google Patents
Verwendung von vip analoge für vorbeugung und behandlung von gehirnbeschädigungen von menschlichen neugeborenenInfo
- Publication number
- ATE218363T1 ATE218363T1 AT99907701T AT99907701T ATE218363T1 AT E218363 T1 ATE218363 T1 AT E218363T1 AT 99907701 T AT99907701 T AT 99907701T AT 99907701 T AT99907701 T AT 99907701T AT E218363 T1 ATE218363 T1 AT E218363T1
- Authority
- AT
- Austria
- Prior art keywords
- lys
- vip
- brain damage
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9803125A FR2775902B1 (fr) | 1998-03-13 | 1998-03-13 | Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain |
PCT/FR1999/000563 WO1999047159A1 (fr) | 1998-03-13 | 1999-03-12 | Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE218363T1 true ATE218363T1 (de) | 2002-06-15 |
Family
ID=9524030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99907701T ATE218363T1 (de) | 1998-03-13 | 1999-03-12 | Verwendung von vip analoge für vorbeugung und behandlung von gehirnbeschädigungen von menschlichen neugeborenen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1061945B1 (de) |
AT (1) | ATE218363T1 (de) |
CA (1) | CA2322018A1 (de) |
DE (1) | DE69901690T2 (de) |
ES (1) | ES2178393T3 (de) |
FR (1) | FR2775902B1 (de) |
WO (1) | WO1999047159A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972319B1 (en) | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
SK5552002A3 (en) * | 1999-09-28 | 2003-05-02 | Bayer Ag | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
US7507714B2 (en) | 2000-09-27 | 2009-03-24 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
WO2009043447A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105061A (en) * | 1993-03-16 | 2000-11-21 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof |
DE69735991D1 (de) * | 1996-02-09 | 2006-07-06 | Hoffmann La Roche | Herstellung eines vip-analogen |
-
1998
- 1998-03-13 FR FR9803125A patent/FR2775902B1/fr not_active Expired - Fee Related
-
1999
- 1999-03-12 ES ES99907701T patent/ES2178393T3/es not_active Expired - Lifetime
- 1999-03-12 AT AT99907701T patent/ATE218363T1/de not_active IP Right Cessation
- 1999-03-12 WO PCT/FR1999/000563 patent/WO1999047159A1/fr active IP Right Grant
- 1999-03-12 EP EP99907701A patent/EP1061945B1/de not_active Expired - Lifetime
- 1999-03-12 CA CA002322018A patent/CA2322018A1/fr not_active Abandoned
- 1999-03-12 DE DE69901690T patent/DE69901690T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2775902A1 (fr) | 1999-09-17 |
EP1061945A1 (de) | 2000-12-27 |
ES2178393T3 (es) | 2002-12-16 |
FR2775902B1 (fr) | 2001-05-11 |
EP1061945B1 (de) | 2002-06-05 |
DE69901690T2 (de) | 2003-02-13 |
CA2322018A1 (fr) | 1999-09-23 |
WO1999047159A1 (fr) | 1999-09-23 |
DE69901690D1 (de) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3019901T3 (en) | Osteoinductive pharmaceutical formulations | |
ATE266043T1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
HK1024261A1 (en) | Reconstituted human anti-hm 1-24 antibody | |
HUP0100928A2 (hu) | Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
DE69931793D1 (de) | Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins | |
DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
HUP0101317A2 (hu) | Módosított VIII-as faktor | |
NO920125L (no) | Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fritt protein s eller protein c i en plasmaproeve | |
ATE290315T1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
ATE253078T1 (de) | Analoge des parathormons zur behandlung der osteoporose | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
IL145310A0 (en) | Vascular adhesion molecules and modulation of their function | |
MXPA02000465A (es) | Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6. | |
DE69405919T2 (de) | Zusammensetzungen zur Behandlung von Keratinfasern | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
DE68921413D1 (de) | Verbindungen und Zusammensetzungen zur Anwendung bei Methoden zur Behandlung und Prophylaxe von Pneumocystis Carinii Pneumonia und anderen Krankheiten. | |
ATE218363T1 (de) | Verwendung von vip analoge für vorbeugung und behandlung von gehirnbeschädigungen von menschlichen neugeborenen | |
DE69835519D1 (de) | Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind. | |
ATE218334T1 (de) | Verwendung von gabapentin in der behandlung vonangst - und panikstörungen | |
ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
ATE121626T1 (de) | Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut. | |
DE69509673D1 (de) | Peptide zur behandlung von allergien | |
ATE427955T1 (de) | Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |